The rest is here:
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2020 Financial Results
Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Sickle Cell Disease
Change in Number of Shares and Votes in Immunicum AB (publ)
Read the original here:
Change in Number of Shares and Votes in Immunicum AB (publ)
Kannalife, Inc. Rebrands as Neuropathix, Inc. and Unveils New Ticker Symbol
Continue reading here:
Kannalife, Inc. Rebrands as Neuropathix, Inc. and Unveils New Ticker Symbol
MediciNova Announces Presentation of Positive Findings on MN-001 (tipelukast) in Acute Liver Injury Model at The Liver Meeting Digital Experience™…
Aileron Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights
Intercept to Announce Third Quarter 2020 Financial Results on November 9, 2020
Go here to see the original:
Intercept to Announce Third Quarter 2020 Financial Results on November 9, 2020
CalciMedica Appoints Daniel Geffken as Interim Chief Financial Officer
Read more from the original source:
CalciMedica Appoints Daniel Geffken as Interim Chief Financial Officer
Satsuma Pharmaceuticals to to participate in the following November Virtual Investor Conferences
Nabriva Therapeutics to Report Third Quarter 2020 Financial Results on November 5, 2020
VYNE Therapeutics to Report Third Quarter 2020 Financial Results on November 5th
Read the rest here:
VYNE Therapeutics to Report Third Quarter 2020 Financial Results on November 5th
Genmab and ADC Therapeutics Announce Amended Agreement for Camidanlumab Tesirine (Cami)
Pandion Therapeutics Highlights Potential of Modular Biologics Pipeline for the Treatment of Autoimmune Diseases at FOCIS 2020
Rhythm Pharmaceuticals Appoints Jennifer Chien as Executive Vice President, Head of North America
Kane Biotech builds upon successful results with launch of a US Consumer Test
Yield10 Bioscience Announces Start of Field Tests of Winter Camelina Varieties
Scout Bio Advances Novel Gene Therapy for the Treatment of Feline Diabetes
AXIM® Biotechnologies Issues Update Letter to Shareholders
Originally posted here:
AXIM® Biotechnologies Issues Update Letter to Shareholders